Alliance Pharma Regulatory News (APH)

For immediate release

 29 June 2023

Name of applicant:

ALLIANCE PHARMA PLC

Names of schemes:

a) The Alliance Pharma plc Approved Share Option Plan 2005

b) The Alliance Pharma plc Share Option Plan 2006

c) The Alliance Pharma plc Company Share Option Plan 2015

d) The Alliance Pharma plc Long-Term Incentive Plan 2019

Period of return:

From:

28 December 2022

To:

28 June 2023

Number of securities originally admitted at date of admission:

25,000,000 ordinary shares of 1p each

28 June 2017

Balance of unallotted securities under schemes from previous return:

a) 149,637

b) 2,551,168

c) 9,572,622

d) 1,341,116

Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):

a) Nil

b) Nil

c) Nil

d) Nil

Less:  Number of securities issued/allotted under schemes during period:

a) 91,715

b) 63,422

c) 0

d) 0

Equals:  Balance under schemes not yet issued/allotted at end of period:

e) 57,922

f) 2,487,746

g) 9,572,622

h) 1,341,116

Name of contact:

Chris Chrysanthou, Company Secretary

Telephone number of contact:

Tel. +44 (0)1249 705166

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

alliancepharma@buchanan.uk.com

Numis Securities Limited (Nominated Adviser and Corporate Broking)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Broking: Patrick Robb